|
|
|
|
||
"Unblinded clinical data expected 2021"Another non event low quality virtual conference presentation by Londoner. Key points- The clinical data presentation is due summer 2021. This is the continuation of the very early small trial data presented by Julie Stephenson in September. One must ask what the hell BSGM has been doing for 3 years? PureEp received FDA 510 clearance summer 2018. PureEp was installed at Mayo years ago and used in preclinical and clinical trials. Why has it taken 3 years for a clinical trial when FDA already cleared the device? THREE YEARS!!! For a cleared device. Doesnt seem like Londoner was in a rush to get this to market. Recall when BSGM was first recommended and pumped on these Boards the thesis was that no clinical trial data was needed. The big hospital and major EP complexes would not need clinical trial data "only the second tier hospitals would" according to the fraud car guy. After HRS 2019 he said "30 hospitals were ready to buy". The data better be better than the early readouts. According to multiple presentations "Drs chose PureEp 35% of the time". Meaning 65% or two thirds of the time PureEp signals were no better. The data will not compel CMOs and capital budget committees to buy PureEp. Imagine your hospital budget is stretched and decimated and an EP cardiologist wants you to spend $220K for an add on device plus another $50k annual expense and the device is only better than existing technology one third of the time. If PureEp was such a game changer and an obvious improvement Mayo would have bought by now. If this improves outcomes and saves lives Mayo and other hospitals with placements would have gone to contract. Ask yourself why the delay- BECAUSE PUREEP IMPROVES SIGNALS ONLY 35% OF THE TIME!!!! I still think Mayo or another hospital will buy one but the length of time to commit is very telling! I think that's why BSGM is dragging its feet. Keep the pay day alive. Keep paying themselves big bucks plus stock while they raise cash in the capital markets (ATM - shelf registration). Soon the pivot to Nueroclear and electromedicine. BSGM has $28mill in cash and Londoner said will last "well into next year". He has said that very exact thing for 3 years and has done secondary after secondary, private raise after private raise and currently selling stock through the Jefferies ATM. The strategy is obvious. Highlight the total addressable EP market. Pretend PureEp will penetrate and participate an that large profitable market. Then raise capital and pay executives and Board a fortune. Not a comment from eatshits and car guy - LOL This is from Eatshts on the ZIOP Board " Unless a BOD member needs the money they get paid for being on the BOD (in which case we have a bigger problem- Why should they be on the BOD if they need that $ to survive), it isn't a big ask to have them use 1/3 of the money to buy ZIOP stock on the open market. Plain and simple. All the people on the BOD should be able to work hard and chew gum at the same time. Arranging a stock buy isn't going to take up much of their time. It's a BOD position. Fit it in between NCAA games, or between episodes of Winter Soldier or Hallmark movies they watch. Heck, I'm sure they all have financial advisors or can tap a ZIOP resource to help them walk through the process. No excuses. They want on the team, then show it. And make a habit of it. If ZIOP Board should buy what about the 9 person BSGM Board? They get paid cash and given free stock. In many cases the stock vests immediately ( unheard of!) - Not to mention the Board of ViralClear and Zeldis that took the money and stock and ran. All funded by shareholders. |
return to message board, top of board |